Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics (NASDAQ:MRSN) has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company granted a restricted stock unit (RSU) award to one new employee who joined in March 2025. The award consists of 26,790 shares of common stock.
The RSU award will vest in four equal annual installments starting from February 15, 2025, contingent on the employee's continued service with Mersana. The grant is subject to Mersana's 2022 Inducement Stock Incentive Plan and RSU agreement terms.
Mersana Therapeutics (NASDAQ:MRSN) ha annunciato un'indennità di incentivo ai sensi della Regola di Quotazione Nasdaq 5635(c)(4). L'azienda ha conferito un premio in unità azionarie riservate (RSU) a un nuovo dipendente che è entrato in azienda a marzo 2025. Il premio consiste in 26.790 azioni ordinarie.
Il premio RSU maturerà in quattro rate annuali uguali a partire dal 15 febbraio 2025, a condizione che il dipendente continui a lavorare con Mersana. Il conferimento è soggetto ai termini del Piano di Incentivi Azionari per Indennità 2022 di Mersana e dell'accordo RSU.
Mersana Therapeutics (NASDAQ:MRSN) ha anunciado una concesión de incentivo bajo la Regla de Cotización Nasdaq 5635(c)(4). La empresa otorgó una unidad de acción restringida (RSU) a un nuevo empleado que se unió en marzo de 2025. El premio consiste en 26,790 acciones ordinarias.
La concesión de RSU se consolidará en cuatro cuotas anuales iguales a partir del 15 de febrero de 2025, condicionado a la continuación del servicio del empleado con Mersana. La concesión está sujeta al Plan de Incentivos de Acciones por Inducción de Mersana de 2022 y a los términos del acuerdo RSU.
Mersana Therapeutics (NASDAQ:MRSN)는 Nasdaq 상장 규정 5635(c)(4)에 따라 유인 보상을 발표했습니다. 회사는 2025년 3월에 합류한 신입 직원에게 제한 주식 단위(RSU) 보상을 부여했습니다. 이 보상은 26,790주로 구성되어 있습니다.
RSU 보상은 2025년 2월 15일부터 시작하여 직원이 Mersana에서 계속 근무하는 조건으로 4회에 걸쳐 연간 균등하게 분할 지급됩니다. 이 보상은 Mersana의 2022 유인 주식 인센티브 계획 및 RSU 계약 조건에 따릅니다.
Mersana Therapeutics (NASDAQ:MRSN) a annoncé une attribution d'incitation conformément à la règle de cotation Nasdaq 5635(c)(4). L'entreprise a accordé une unité d'actions restreintes (RSU) à un nouvel employé qui a rejoint en mars 2025. L'attribution se compose de 26 790 actions ordinaires.
L'attribution RSU sera acquise en quatre versements annuels égaux à partir du 15 février 2025, sous réserve que l'employé continue à travailler avec Mersana. L'attribution est soumise aux conditions du Plan d'Incitation aux Actions de Mersana de 2022 et aux termes de l'accord RSU.
Mersana Therapeutics (NASDAQ:MRSN) hat eine Anreizgewährung gemäß der Nasdaq-Listing-Regel 5635(c)(4) angekündigt. Das Unternehmen hat einem neuen Mitarbeiter, der im März 2025 eingetreten ist, eine eingeschränkte Aktieneinheit (RSU) gewährt. Die Auszeichnung besteht aus 26.790 Stammaktien.
Die RSU-Auszeichnung wird in vier gleichen jährlichen Raten ab dem 15. Februar 2025 fällig, vorausgesetzt, der Mitarbeiter bleibt weiterhin bei Mersana beschäftigt. Die Gewährung unterliegt den Bedingungen des Mersana 2022 Anreiz-Aktien-Plan und des RSU-Vereins.
- None.
- None.
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2025, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 26,790 shares of its common stock, to one new employee whose employment commenced in March 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU award is subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering the grant.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
What is the size of Mersana Therapeutics' (MRSN) latest RSU inducement grant?
What is the vesting schedule for MRSN's April 2025 inducement grant?
When was the MRSN inducement grant approved?
Under which regulatory rule was MRSN's inducement grant issued?
